-
Airbus aims for record deliveries despite disappointing quarter
-
US Fed holds interest rates steady despite surging inflation
-
Cuba wins UN vote against US embargo with weakest backing in 30 years
-
Chiefs sign ex-Ravens kicker suspended over sex allegations
-
Real Madrid, La Liga apology over Mbappe shows power of Chinese market
-
Inglis and Carey put Australia in command of South Africa decider
-
From Gaza to Ramallah, Palestinians see little hope in Israeli vote
-
92-year-old US judge handling Maduro case dies
-
US labor leader Dolores Huerta dead: family
-
Perez extends Cadillac deal to 2029
-
Investors turn cautious ahead of tech results, Fed update on rates
-
Arab Israelis proud of high election turnout, uncertain for future
-
'Cruise for life' strands passengers in Cambodia as operator goes bust
-
Inglis, Carey put Australia in command of South Africa decider
-
Bolsonaro flees Brazil for US after election defeat
-
French firm Safran helps build aircraft wings of the future in UK factory
-
A throne on wheels, popemobiles star in new Vatican show
-
Ceasefire in Russia-occupied Ukrainian city holds for second day
-
Spain high-speed train crash kills 68, injures over 100
-
Canada hikes rates to contain oil price surge caused by Iran war
-
UK woman drugged by husband tells rape trial she woke up bound
-
World Bank warns of worsening food insecurity as commodity prices soar
-
Clean-up starts as Serbian students movement prepares to govern
-
Mona Lisa scrubbed from Syrian textbooks as critics slam conservative drift
-
Flavio Bolsonaro: right-wing heir falls from presidential hopeful to exile
-
Bolsonaro flees Brazil for US after election defeat: AFP
-
UK budget lifts bank tax to offset surging energy bills
-
Brazil's Bolsonaros: between power, prison, and exile
-
Spain high-speed train collision kills 64, injures over 100
-
Israel president urges against new vote despite inconclusive result
-
Brazil's Bolsonaro lands in Florida after election defeat: AFP
-
Eala recovers to move into Tokyo quarter-finals
-
Russia woos African leaders at Moscow summit
-
COPs 'bunch of baloney' says Panama as it vies to host nature summit
-
Local ceasefire in Russia-occupied Ukrainian city holds for second day
-
Denmark mulls banning turbo chickens
-
Odegaard urges Arsenal to move on after Fleetwood upset
-
Nintendo producer 'all nervous' as Zelda classic remake hits shelves
-
Japan, Germany leaders target closer ties on critical minerals
-
Israeli Arab parties hold key as Netanyahu falls short of majority
-
Spain high-speed train collision kills 31, injures 80
-
UK comedian Brand tells rape trial 'consent is fundamental'
-
Turkey hosted Libya east-west reunification talks last week
-
Shadman guides Bangladesh to 213-3 in West Indies Test
-
Spain high-speed train collision kills 30
-
Tech optimism lifts stocks ahead of Fed update on rates
-
Plane reportedly carrying Brazil's Bolsonaro departs Ecuador
-
No penalty practice for Fleetwood hero Haughey before he downs Arsenal
-
Springboks pick six uncapped players for Nations Championship
-
Billionaire Ambani's Jio soars in market debut after India's biggest IPO
Study shows how fast kilos return after ending weight-loss drugs
When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.
But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.
A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.
They have been found to help people lose between 15-20 percent of their body weight.
"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.
However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.
This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.
So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.
Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.
While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.
However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.
The researchers projected that the participants would return to their original weight in 18 months.
Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.
People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.
This meant that people taking the drugs regained their weight four times faster.
- 'Starting point, not a cure' -
"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.
But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.
This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.
Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."
"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.
If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.
"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.
"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.
A.Kunz--VB